The Pfizer Starna licensing agreement, announced on November 18, 2026, gives Pfizer Inc. (NYSE: PFE) exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs from Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. The programs focus on treating autoimmune diseases.
Beyond the three programs, Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology. The company additionally holds options to exclusively license compounds created under a separate research collaboration, plus an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in Greater China.
Financially, Starna will receive an upfront payment of $330 million. It is also eligible for up to $2.3 billion in milestone payments tied to certain development and commercial milestones, plus royalties on net sales of approved products. Every figure in this report comes from Pfizer’s own release, and terms the company has not published are labeled as not disclosed.
What the Pfizer Starna Licensing Agreement Covers for In Vivo CAR-T Programs
At the center of the Pfizer Starna licensing agreement are three programs the release describes as pre-IND. Pfizer’s announcement does not name the programs, their molecular targets or the specific autoimmune diseases each will address, so those details are not disclosed. What the company does confirm is the scope of its rights: development, manufacturing and commercialization, all outside Greater China.
Michael Vincent, M.D., Ph.D., Pfizer’s Chief Inflammation & Immunology Officer, called in vivo CAR-T an “emerging and promising approach” for autoimmune diseases. He said the patients who may benefit most are those for whom current options fall short, and pointed to Pfizer’s experience developing and manufacturing RNA based medicines globally, adding that Starna’s programs and technology give Pfizer a strong route into the approach.
Rongkuan Hu, Ph.D., Chief Executive Officer of Starna Therapeutics, said the company’s vision is to unlock the potential of RNA medicines for patient care. He described Starna’s proprietary targeted LNP delivery platform and RNA technology as a strong foundation for advancing in vivo CAR-T therapies, and described the Pfizer Starna licensing agreement as a chance to join forces with a global leader in drug development.
Starna Therapeutics is described in the release as a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Its chief executive points to a targeted LNP delivery platform as part of that approach. The release gives no information about Starna’s headquarters, funding history, employee count or other pipeline assets, so those facts are not disclosed here.
Pfizer Starna Licensing Agreement Deal Terms: $330 Million Upfront and $2.3 Billion in Milestones
The headline economics of the Pfizer Starna licensing agreement combine a $330 million upfront payment with potential milestone payments of up to $2.3 billion. Adding the two gives a ceiling of roughly $2.63 billion before royalties, a figure derived from the release rather than stated in it. Starna is also eligible for royalties on net sales of approved products, but the royalty rates and the split of milestones between development and commercial events are not disclosed.
Territory is the other defining term. Pfizer’s exclusive rights apply outside Greater China, while an option lets Pfizer expand that footprint to include Greater China for each exclusively licensed compound and product. The terms of that option, including any fee or exercise period, are not disclosed in the release.
Operationally, Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials at its facilities in the United States. Pfizer will also hold sole and exclusive control over commercialization outside Greater China for all products. Under the Pfizer Starna licensing agreement, therefore, clinical development, initial manufacturing and commercial decisions in the licensed territory rest with Pfizer.
Strategic Impact of the Pfizer Starna Licensing Agreement on Pfizer’s Inflammation & Immunology Pipeline
According to the release, the agreement broadens Pfizer’s Inflammation & Immunology pipeline. It lets Pfizer apply its scientific expertise in RNA delivery, along with its specialization in immunology research, clinical development and commercialization, to what the company calls a promising, next generation approach in cell therapy.
Oncology is a second front. Because the Pfizer Starna licensing agreement grants rights to Starna’s proprietary in vivo CAR-T technology in oncology as well as inflammation and immunology, Pfizer says the technology offers future opportunities to design potentially transformative autoimmune and cancer treatments. No oncology program, indication or timeline is named in the announcement.
Pfizer describes its mission as applying science and global resources to bring therapies that extend and significantly improve patients’ lives. The company says it has worked for over 175 years across developed and emerging markets and collaborates with health care providers, governments and local communities to expand access to reliable, affordable health care. It routinely posts investor relevant information on its website.
What the Pfizer Starna Licensing Agreement Does Not Disclose and What Comes Next
Several material points of the Pfizer Starna licensing agreement remain undisclosed. Pfizer does not name the three programs or their targets, does not give royalty rates or a milestone breakdown, and does not describe the economics of the research collaboration or the exercise terms of its options.
As with any forward looking announcement, the benefits of the Pfizer Starna licensing agreement are not guaranteed. Pfizer’s disclosure notice lists risks including failure to realize anticipated benefits, integration of the licensed programs, transaction costs, possible litigation or regulatory actions, manufacturing capacity, and the uncertainties inherent in preclinical and clinical research. The company states the information is current as of November 18, 2026, and that it assumes no obligation to update forward looking statements.
Pfizer Starna Licensing Agreement Snapshot:
| Attribute | Detail |
|---|---|
| Announcement date | November 18, 2026 |
| Dateline / distribution | New York, via Business Wire |
| Licensee | Pfizer Inc. (NYSE: PFE) |
| Licensor | Starna Therapeutics |
| Starna description | Biotechnology company developing RNA medicines designed to enable in vivo therapeutics |
| Licensed assets | Three pre-IND in vivo CAR-T programs for autoimmune diseases |
| Technology rights | Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology |
| Release category | Corporate, Research and Pipeline |
Financial Terms:
| Term | Detail |
|---|---|
| Upfront payment to Starna | $330 million |
| Milestone payments | Up to $2.3 billion (development and commercial milestones) |
| Royalties | On net sales of approved products; rates not disclosed |
| Combined upfront plus maximum milestones | Approx. $2.63 billion (derived by adding the two stated figures; not stated in the release) |
| Milestone breakdown | Not disclosed |
Rights and Responsibilities:
| Area | Pfizer | Starna |
|---|---|---|
| Development outside Greater China | Leads clinical development | Not disclosed |
| Manufacturing | Plans to manufacture finished drug product for initial clinical trials at US facilities | Not disclosed |
| Commercialization outside Greater China | Sole and exclusive control, all products | None stated |
| Greater China | Option to expand territory | Not disclosed |
| Separate research collaboration | Options to exclusively license resulting compounds | Not disclosed |
Disclosed vs. Not Disclosed:
| Item | Status |
|---|---|
| Number of programs | Disclosed: three |
| Development stage | Disclosed: pre-IND |
| Therapeutic area | Disclosed: autoimmune diseases (plus oncology technology rights) |
| Program names and targets | Not disclosed |
| Royalty rates | Not disclosed |
| Option fees and exercise periods | Not disclosed |
| First clinical trial timeline | Not disclosed |
| Starna funding, headquarters, other pipeline | Not disclosed |



